Lantern Pharma (LTRN) Tops Q2 EPS by 2c

Lantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.44), $0.02 better than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform